In September 2024, the “Clinical Practice Guidelines for the Management of Hypertension in China” was officially released by the Chinese Society of Cardiology, Chinese Medical Association and other academic institutions.The guideline encompasses 98 recommendations for 44 key clinical issues in the management of hypertension. This article presents a concise summary of 10 highlights of the guideline, including the scientific foundation of the guideline, the concept and definition of prehypertension, simplified risk stratification for hypertension, antihypertensive treatment initiation timing, antihypertensive targets for different populations, first-line antihypertensive drugs, antihypertensive programs for various clinical complications, non-drug therapies, indications for renal denervation, and screening for secondary hypertension, in order to help doctors better understand the guidelines, promote their implementation, and guide clinical practice.